GlassScriptPhysician profile
Anay Vallejo
NPI 1225513963
$13,208.59
in general payments reported to CMS, 2019-2025
50 companies · $3,091 in 2025
The $3,091 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $2,618 · 2023: $2,831 · 2024: $3,082 · 2025: $3,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,915 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,914.71 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,603.46 | 2021-2025 | |
| Amgen INC. | $2,236.81 | 2021-2025 | Enbrel, Evenity, Prolia |
| Janssen Biotech, INC. | $1,391.80 | 2021-2025 | Tremfya, Simponi Aria, Talvey |
| Astrazeneca Pharmaceuticals LP | $1,278.55 | 2021-2025 | Saphnelo, Enhertu, Imfinzi |
| Tersera Therapeutics LLC | $629.64 | 2022-2025 | Quzyttir, Zoladex, Xermelo |
| Glaxosmithkline, LLC. | $508.84 | 2021-2025 | Benlysta |
| Ucb, INC. | $502.03 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $473.30 | 2022-2025 | |
| Lilly USA, LLC | $471.17 | 2021-2024 | Taltz |
| Pfizer INC. | $315.98 | 2021-2025 | |
| Horizon Therapeutics Plc | $286.49 | 2021-2023 | Krystexxa |
| Organon LLC | $272.25 | 2022-2025 | Hadlima, Renflexis |
| Takeda Pharmaceuticals U.S.A., INC. | $217.76 | 2022-2025 | Ninlaro, Alunbrig, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $216.53 | 2021-2025 | Orencia |
| Incyte Corporation | $140.13 | 2021-2025 | Monjuvi, Jakafi |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anay Vallejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.